KR101970509B1 - 5-히드록시-1h-이미다졸-4-카르복사미드 수화물의 결정, 5-히드록시-1h-이미다졸-4-카르복사미드·3/4 수화물의 결정 및 그 제조 방법 - Google Patents

5-히드록시-1h-이미다졸-4-카르복사미드 수화물의 결정, 5-히드록시-1h-이미다졸-4-카르복사미드·3/4 수화물의 결정 및 그 제조 방법 Download PDF

Info

Publication number
KR101970509B1
KR101970509B1 KR1020147008200A KR20147008200A KR101970509B1 KR 101970509 B1 KR101970509 B1 KR 101970509B1 KR 1020147008200 A KR1020147008200 A KR 1020147008200A KR 20147008200 A KR20147008200 A KR 20147008200A KR 101970509 B1 KR101970509 B1 KR 101970509B1
Authority
KR
South Korea
Prior art keywords
hydroxy
imidazole
hydrate
carboxamide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147008200A
Other languages
English (en)
Korean (ko)
Other versions
KR20140069052A (ko
Inventor
타이스케 후지모토
토모히로 하시모토
카츠유키 하야시
토모유키 타나카
Original Assignee
후지필름 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 후지필름 가부시키가이샤 filed Critical 후지필름 가부시키가이샤
Publication of KR20140069052A publication Critical patent/KR20140069052A/ko
Application granted granted Critical
Publication of KR101970509B1 publication Critical patent/KR101970509B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
KR1020147008200A 2011-09-28 2012-09-28 5-히드록시-1h-이미다졸-4-카르복사미드 수화물의 결정, 5-히드록시-1h-이미다졸-4-카르복사미드·3/4 수화물의 결정 및 그 제조 방법 Expired - Fee Related KR101970509B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2011213500 2011-09-28
JPJP-P-2011-213500 2011-09-28
JP2011213501 2011-09-28
JPJP-P-2011-213501 2011-09-28
PCT/JP2012/075106 WO2013047758A1 (ja) 2011-09-28 2012-09-28 ５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミド水和物の結晶及び５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミド・３／４水和物の結晶及びその製造方法

Publications (2)

Publication Number Publication Date
KR20140069052A KR20140069052A (ko) 2014-06-09
KR101970509B1 true KR101970509B1 (ko) 2019-04-19

Family

ID=47995783

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147008200A Expired - Fee Related KR101970509B1 (ko) 2011-09-28 2012-09-28 5-히드록시-1h-이미다졸-4-카르복사미드 수화물의 결정, 5-히드록시-1h-이미다졸-4-카르복사미드·3/4 수화물의 결정 및 그 제조 방법

Country Status (13)

Country Link
US (2) US9108928B2 (enExample)
EP (1) EP2762469B1 (enExample)
KR (1) KR101970509B1 (enExample)
CN (1) CN103827093B (enExample)
AU (1) AU2012317424B2 (enExample)
BR (1) BR112014007436A2 (enExample)
CA (1) CA2850196A1 (enExample)
IL (2) IL231677A (enExample)
IN (1) IN2014CN02346A (enExample)
MX (1) MX354498B (enExample)
RU (2) RU2630682C2 (enExample)
SG (1) SG11201400974VA (enExample)
WO (1) WO2013047758A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101970509B1 (ko) 2011-09-28 2019-04-19 후지필름 가부시키가이샤 5-히드록시-1h-이미다졸-4-카르복사미드 수화물의 결정, 5-히드록시-1h-이미다졸-4-카르복사미드·3/4 수화물의 결정 및 그 제조 방법
WO2014112529A1 (ja) * 2013-01-15 2014-07-24 富士フイルム株式会社 ５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミドの硫酸塩
JP6294357B2 (ja) 2014-01-10 2018-03-14 富士フイルム株式会社 ５−ヒドロキシ−１ｈ−イミダゾール−４−カルボキサミドの有効投与量または感受性の予測方法および予測装置、キサントシン一リン酸の量の測定方法ならびに骨髄異形成症候群の処置剤および処置方法
WO2018051971A1 (ja) * 2016-09-13 2018-03-22 富士フイルム株式会社 Ｍｌｌ関連白血病の予防または治療のための医薬、方法、使用及び化合物
EP3686189B1 (en) * 2017-10-27 2021-09-01 FUJIFILM Corporation Production method for 5-hydroxy-1h-imidazole-4-carboxamide-3/4hydrate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181731A (en) * 1976-09-07 1980-01-01 Sumitomo Chemical Company, Limited Novel therapeutic application of 4-carbamoyl-5-hydroxyimidazole
JPS5625165A (en) * 1979-08-08 1981-03-10 Sumitomo Chem Co Ltd Novel imidazole derivative
JPS5824569A (ja) 1981-08-05 1983-02-14 Sumitomo Chem Co Ltd イミダゾ−ル誘導体の精製方法
US4503235A (en) * 1983-03-11 1985-03-05 Warner-Lambert Company Process for producing 4-carbamoyl-1H-imidazolium-5-olate
JPS60185727A (ja) * 1984-03-05 1985-09-21 Sumitomo Chem Co Ltd ４−カルバモイルイミダゾリウム−５−オレ−ト製剤の安定化法
CA2152863A1 (en) 1994-07-26 1996-01-27 Yeun-Kwei Han Preparation of acyclovir
US5567816A (en) 1994-07-26 1996-10-22 Syntex (U.S.A.) Inc. Preparation of acyclovir using 1,3 dioxolane
JP2004509948A (ja) 2000-09-29 2004-04-02 ビーエーエスエフ　アクチェンゲゼルシャフト １−置換−５−クロロ−４−メチルピラゾールの製造方法
JP2002265601A (ja) 2001-03-07 2002-09-18 Rikogaku Shinkokai イミド樹脂
AU2006215567B2 (en) * 2005-02-16 2011-05-12 Abbott Healthcare Products B.V. 1H-imidazole derivatives as cannabinoid CB2 receptor modulators
UA94737C2 (ru) * 2006-02-24 2011-06-10 Лексикон Фармасьютикалз, Инк. Соединения на основе имидазола, композиция, которая их содержит, и их применение
JP5266010B2 (ja) * 2007-09-14 2013-08-21 富士フイルム株式会社 ４−カルバモイル−５−ヒドロキシ−イミダゾール誘導体のスルホン酸塩化合物
KR100982720B1 (ko) * 2008-02-04 2010-09-17 주식회사 파마코스텍 4-카르바모일-1-β-Ｄ-리보푸라노실이미다졸륨-5-올레이트의 생산을 위한 중간체로서의 2-아미노말론아미드의제조방법
KR101970509B1 (ko) 2011-09-28 2019-04-19 후지필름 가부시키가이샤 5-히드록시-1h-이미다졸-4-카르복사미드 수화물의 결정, 5-히드록시-1h-이미다졸-4-카르복사미드·3/4 수화물의 결정 및 그 제조 방법
JP5726830B2 (ja) 2011-09-28 2015-06-03 富士フイルム株式会社 ５−ヒドロキシ−１ｈ−イミダゾール−４−カルボキサミド・３／４水和物の結晶及びその製造方法

Also Published As

Publication number Publication date
KR20140069052A (ko) 2014-06-09
MX2014003638A (es) 2014-05-21
AU2012317424A1 (en) 2014-04-17
SG11201400974VA (en) 2014-09-26
EP2762469A4 (en) 2015-01-14
WO2013047758A1 (ja) 2013-04-04
IL246754A (en) 2017-08-31
MX354498B (es) 2018-03-08
IN2014CN02346A (enExample) 2015-06-19
NZ622928A (en) 2015-04-24
EP2762469A1 (en) 2014-08-06
US20140275568A1 (en) 2014-09-18
EP2762469B1 (en) 2016-11-23
CN103827093A (zh) 2014-05-28
CN103827093B (zh) 2016-06-15
HK1197406A1 (zh) 2015-01-16
RU2672560C1 (ru) 2018-11-16
IL231677A0 (en) 2014-05-28
US9108928B2 (en) 2015-08-18
AU2012317424B2 (en) 2017-05-18
AU2012317424A8 (en) 2014-07-03
US9567303B2 (en) 2017-02-14
RU2014111810A (ru) 2015-11-10
IL231677A (en) 2017-01-31
BR112014007436A2 (pt) 2017-04-04
RU2630682C2 (ru) 2017-09-12
CA2850196A1 (en) 2013-04-04
US20150315156A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
US20240083902A1 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
KR101970509B1 (ko) 5-히드록시-1h-이미다졸-4-카르복사미드 수화물의 결정, 5-히드록시-1h-이미다졸-4-카르복사미드·3/4 수화물의 결정 및 그 제조 방법
JP2017160243A (ja) ７−｛（３ｓ、４ｓ）−３−［（シクロプロピルアミノ）メチル］−４−フルオロピロリジン−１−イル｝−６−フルオロ−１−（２−フルオロエチル）−８−メトキシ−４−オキソ−１、４−ジヒドロキノリン−３−カルボン酸の結晶
JP2023544775A (ja) ７－クロロ－６－フルオロ－１－（２－イソプロピル－４－メチルピリジン－３－イル）ピリド［２，３－ｄ］ピリミジン－２，４（１Ｈ，３Ｈ）－ジオンのアトロプ異性体をラセミ化及び単離するためのプロセス
EP3692030B1 (en) Process for the preparation of ridinilazole using acid addition salts
JP5905614B2 (ja) ５−ヒドロキシ−１ｈ−イミダゾール−４−カルボキサミド・３／４水和物の製造方法及びその結晶の製造方法
HK1197406B (en) Crystal of 5-hydroxy-1h-imidazole-4-carboxamide hydrate, crystal of 5-hydroxy-1h-imidazole-4-carboxamide 3/4 hydrate, and method for producing same
EP3397618B1 (en) Process for making crystalline form a of gefitinib
NZ622928B2 (en) Crystal of 5-hydroxy-1h-imidazole-4-carboxamide·3/4 hydrate, method for producing the same and crystal of 5-hydroxy-1 h-imidazole-4-carboxamide hydrate
US9840506B2 (en) Crystal of doripenem, and preparation method therefor
AU2025204582A1 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N- {4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
WO2025193182A1 (en) A new stable crystalline form of roxadustat and preparation method thereof
US20040209898A1 (en) Process for the preparation of risperidone
HK1167647A1 (en) 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220416

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220416